The enteric nervous system (ENS) is often called the "second brain" because it contains over 500 million neurons—more than the spinal cord—and operates largely independently of the central nervous system. The ENS controls gut motility, secretion, blood flow, and immune function. In neurodegenerative diseases, the ENS is among the earliest tissues affected, with alpha-synuclein pathology detectable in gut biopsies years before motor symptoms appear.
Cell Types and Organization
Enteric Neurons
Myenteric (Auerbach's) plexus — located between circular and longitudinal muscle layers; controls motility
Submucosal (Meissner's) plexus — regulates secretion and blood flow
Neuronal subtypes: sensory neurons, interneurons, motor neurons
Critically, the ENS represents a key intersection between the gut and the brain in neurodegenerative disease pathogenesis. The bidirectionally connected gut-brain axis provides a pathway through which intestinal pathology may influence central nervous system function, and vice versa.
Cell Types and Markers
The ENS contains multiple distinct neuronal populations:
Enteric neurons: Cholinergic (excitatory) and nitrergic (inhibitory) neurons controlling motility
Enteric glial cells: Supporting cells analogous to astrocytes, expressing S100β and GFAP
Interneurons: Local circuit neurons coordinating peristalsis
Secretomotor neurons: Controlling intestinal secretion and blood flow
Key molecular markers:
HuC/D (pan-neuronal marker)
ChAT (choline acetyltransferase)
nNOS (neuronal nitric oxide synthase)
CGRP (calcitonin gene-related peptide)
PGP9.5 (ubiquitin C-terminal hydrolase)
Function in Neurodegeneration
Parkinson's Disease
The ENS is prominently affected in Parkinson's disease, with gastrointestinal dysfunction occurring in up to 80% of patients, often years before motor symptoms appear[2]. Pathological features include:
α-Synuclein accumulation: Lewy bodies and Lewy neurites appear in enteric neurons early in PD progression, following the staging scheme proposed by Braak (stages 1-2)[1]
Neuronal loss: Significant reduction in enteric neuron counts, particularly in the submucosal plexus
Gut motility dysfunction: Constipation, delayed gastric emptying, and small intestinal bacterial overgrowth
The ENS may serve as both a site of earliest PD pathology (via vagal nerve propagation to the brain) and a potential biomarker source (via tissue biopsies)[2].
Alzheimer's Disease
Emerging evidence links gut dysfunction to Alzheimer's disease pathology:
Gut-brain axis disruption: Altered gut motility and microbiome composition in AD patients
Intestinal inflammation: Elevated pro-inflammatory cytokines in gut tissue
Barrier dysfunction: Increased intestinal and blood-brain barrier permeability
Metabolite effects: Gut-derived metabolites influencing brain function and neuroinflammation[3]
Amyotrophic Lateral Sclerosis
Gastrointestinal dysfunction is increasingly recognized in ALS:
Malnutrition and weight loss from dysphagia and impaired motility
Altered gut microbiome composition
Potential for gut-derived inflammation to influence motor neuron pathology
Key Interactions
Gut Microbiome-ENS-Brain Axis
The ENS serves as the interface between the gut microbiome and the CNS. Microbial metabolites (short-chain fatty acids, bile acids, tryptophan derivatives) directly influence ENS function and can propagate signals to the brain via:
Vagal afferent pathways
Systemic circulation
Immune system modulation[4]
Enteric Glia-Neuron Interactions
Enteric glial cells support neuronal survival, regulate synaptic transmission, and maintain the intestinal barrier. In neurodegeneration, glial dysfunction may precede and drive neuronal loss.
Autonomic Nervous System Integration
The ENS communicates with the CNS through sympathetic and parasympathetic (vagus) pathways, providing a anatomical route for pathological protein propagation (e.g., α-synuclein from gut to brain)[1].
Clinical Implications
Early biomarkers: Rectal or colonic biopsies can detect early α-synuclein pathology
[Dementia with Lewy Bodies](/diseases/dementia-lewy-bodies)
[Gut-Brain Axis](/mechanisms/gut-brain-axis)
[Alpha-Synuclein](/proteins/alpha-synuclein)
References
[Braak H, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging (2003)](https://pubmed.ncbi.nlm.nih.gov/12446254/)
[Greene JG. The gastrointestinal system in Parkinson's disease. Clin Gastroenterol Hepatol (2019)](https://pubmed.ncbi.nlm.nih.gov/31279910/)
[Needham BD, et al. A gut-derived metabolite alters brain activity and anxiety. Nature (2023)](https://pubmed.ncbi.nlm.nih.gov/37289855/)
[Sampson TR, et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease. Cell (2016)](https://pubmed.ncbi.nlm.nih.gov/27984727/)